Spotlight 21/08/2018 AMR Centre invites members to provide feedback on IACG paper

A public consultation has been launched on a discussion paper, “Reduce unintentional exposure and the need for antimicrobials, and optimize their use,” prepared by the Interagency Coordination Group on Antimicrobial Resistance (IACG). The IACG was established in 2016 with guidance from the World Health Organization (WHO), the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (OIE) The IACG’s mandate is to provide practical guidance for approaches needed to ensure sustained effective global action to address AMR, and to report back to the UN Secretary-General in 2019. Consultation responses are due by 30 August 2018.

The AMR Centre will hold a meeting on Thurs 23 August, from 2 to 4 pm in Room Jerry Morris A, Tavistock Place to discuss and collate responses for the consultation. All are welcome to contribute expertise and experience in person or by Skype (please contact if you are interested to join via Skype)

The discussion paper and other documents can be reviewed here

Key questions posed are:

  1. What kind of support (other than financial) is needed to translate the existing guidance into implementable actions?
  2. How can policy makers be assisted to further develop and implement infection prevention and control in human and animal health and plants and be convinced to invest now to mitigate the escalating and future costs and obtain benefits far beyond preventing AMR?
  3. What incentives or initiatives are needed for behaviour change towards responsible use in the health sector (hospitals, community health centres) and in the food and animal production sectors (animal and plant health professionals, food producers and manufacturers, consumers).
  4. What is needed to generate evidence-based data that link the misuse of antimicrobials and the development and spread of AMR via the environment? How can we use the available data to develop effective policy solutions influence policy makers?
  5. What approaches are needed to ensure the industry and investors manufacture and market antimicrobials responsibly, and not stimulate overuse or contribute to environmental pollution?

By Heidi Hopkins, head of the Clinical & Veterinary Sciences pillar